Avecho Biotechnology Limited's (ASX:AVE) Paul Gavin talks Proactive's Andrew Scott through the news it's received ethics approval for its phase I clinical trial that will characterise the absorption profile of CBD from its TPM-enhanced pharmaceutical product in healthy volunteers. TPM is the company's proprietary drug delivery system. Gavin says approval is the first step towards their primary goal of developing differentiated CBD products for pharmaceutical registration.
Avecho Biotechnology welcomes ethics approval for its phase I CBD clinical trial
